Cochlear Implants
North America · 1 shared keyword
Updated
Reviewed by Chandani Patel
North America Myopia Control Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$4.55 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.79 Bn | — | — |
| 2025 (base) | $2.04 Bn | +$249.5 Mn | — |
| 2026 (forecast) | $2.33 Bn | +$284.1 Mn | +13.9% |
| 2027 (forecast) | $2.65 Bn | +$323.6 Mn | +29.7% |
| 2028 (forecast) | $3.02 Bn | +$368.6 Mn | +47.8% |
| 2029 (forecast) | $3.44 Bn | +$419.8 Mn | +68.3% |
| 2030 (forecast) | $3.92 Bn | +$478.2 Mn | +91.7% |
| 2031 (forecast) | $4.46 Bn | +$544.7 Mn | +118.3% |
| 2032 (forecast) | $5.08 Bn | +$620.4 Mn | +148.7% |
| 2033 (forecast) | $5.79 Bn | +$706.6 Mn | +183.3% |
| 2034 (forecast) | $6.59 Bn | +$804.8 Mn | +222.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.04 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $6.59 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 13.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, age and end user (see all) |
| Key players | EssilorLuxottica, HOYA, CooperVision, Johnson & Johnson, Santen Pharmaceutical Co Ltd (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Myopia control slows short-sightedness getting worse in children, using special glasses, contact lenses and eye drops.
Key segments of the myopia Control market include product (Myopia Control Spectacle Lenses, Orthokeratology Lenses and Soft Multifocal Contact Lenses) and age (Children and Teenagers).
An ageing population, more people with diabetes and long-term conditions, better treatments and wider access to specialist care are driving the myopia Control market.
Longer-acting treatments, home-based care and screening in emerging markets give the myopia Control market room to grow.
High costs of new treatments, specialist shortages, low awareness and limited reimbursement in some countries hold back the myopia Control market.
The myopia Control market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the countries we cover here, medical devices are regulated by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4].
[1] Health Canada. Checked 14 Nov 2026.
[2] US Food and Drug Administration. Checked 14 Nov 2026.
[3] Health Canada. Checked 14 Nov 2026.
[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how myopia Control products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in North America.
What doctors and scientists are doing in Myopia Control right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
North America · 1 shared keyword
North America
North America
North America
North America
North America
Digital Health · North America
Healthcare Services · North America
Pharmaceuticals · North America
Pharmaceuticals · North America
Pharmaceuticals · North America
Pharmaceuticals · North America